Signs and symptoms of Alzheimer’s disease
We all experience memory issues from time to time.
But experiencing the following more and more often may be an early sign of Alzheimer’s disease:
- Misplacing items or forgetting their names
- Difficulty completing familiar tasks
- Trouble following familiar routes
- Trouble remembering recent conversations
- Trouble remembering words and names
- Difficulty making decisions
What this study involves
The total length of the GRADUATE I study is 3 years, including screening and follow-up. The dosing period of the study will last for 2 years, during which half of the participants will be given the investigational medication and half will be given a placebo (a dummy medication that contains no active ingredients). These will be given as subcutaneous (under the skin) injections at a study hospital or at home, once every 2-4 weeks. Participants will not know which group they have been assigned to. But please be assured that every participant will receive the same close monitoring throughout via regular hospital visits, regardless of their group.
Could GRADUATE I be your next step?
The GRADUATE I clinical study will assess how safe and effective an investigational medication is at slowing the progression of early (also known as ‘prodromal’) or mild Alzheimer’s disease. To qualify, participants must:
- Be 50–90 years old
- Have mild Alzheimer’s disease or memory problems that may be the early symptoms of the condition
- Have someone they see frequently and who is willing to act as their ‘Study Partner’ throughout the duration of this study
What else should I know?
All study-related medications and assessments will be provided at no cost to participants. Travel reimbursement may also be included. Of course, taking part in a clinical study is a personal decision and no one has to join if they don’t want to. It’s also important to know that if participants join the study and then change their mind, they can leave at any time without any impact on their usual healthcare.
